STEVENSON, Md., April 8, 2015 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation encourages former employees of AcelRx Pharmaceuticals, Inc. (“AcelRx”) (Nasdaq:ACRX) with information relating to the issues raised in the U.S. Food and Drug Administration’s July 25, 2014 Complete Response Letter regarding AcelRx’s new drug application for Zalviso, including information relating to the incidence of optical system errors and dispensing errors by the Zalviso System, a needle-free, handheld, patient-administered, pain management system, to contact Brower Piven either by email at trepetin@browerpiven.com or by telephone at (410) 332-0030.
Brower Piven has been appointed lead counsel in a class action lawsuit against AcelRx pending in the United States District Court for the Northern District of California on behalf of purchasers of certain AcelRx securities, including the Company’s common stock.